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ABSTRACT
The main objectives of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are
to harmonise breakpoints for antimicrobial agents in Europe, and to act as the breakpoint committee for
the European Medicines Agency (EMEA) during the registration of new antimicrobial agents. Detailed
EUCAST procedures for harmonising and setting breakpoints for antimicrobial agents are available on
the EUCAST website. Beginning with the current issue, a series of EUCAST Technical Notes will be
published in CMI, based on the rationale documents produced by EUCAST for each of the antimicrobial
agents studied, with the aim of highlighting important background information underlying decisions on
breakpoints made by EUCAST.
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EUCAST is the European Committee on Antimi-
crobial Susceptibility Testing. The main objectives
of EUCAST are to harmonise antimicrobial break-
points in Europe [1,2] and to act as the breakpoint
committee for the European Medicines Agency
(EMEA) during the registration of new antimi-
crobial agents, as defined in a Standard Operating
Procedure agreed between the EMEA, EUCAST
and the pharmaceutical industry in 2005 [3]. An
informal interchange of information exists be-
tween EUCAST and the CLSI (formerly NCCLS)
in the USA. However, differences in structure,
financing and relationships with regulatory
authorities have precluded formal collaboration
in the setting of breakpoints.
EUCAST is convened by the European Society
of Clinical Microbiology and Infectious Diseases
(ESCMID) and the national antimicrobial break-
point committees of France (Comite´ de l’Anti-
biogramme de la Socie´te´ Franc¸aise de
Microbiologie; CA-SFM) [4], Germany (Deutsches
Institut fu¨r Normung; DIN) [5], Norway (Nor-
wegian Working Group on Antimicrobials;
NWGA) [6], Sweden (Swedish Reference Group
of Antibiotics; SRGA) [7], The Netherlands
(Commissie Richtlijnen Gevoeligheidsbepalingen;
CRG) [8] and the UK (British Society for Anti-
microbial Chemotherapy; BSAC) [9]. EUCAST is
financed by ESCMID, the national breakpoint
committees and the 5th Directorate General
(DG-Sanco) of the European Union.
EUCAST has a General Committee, with one
representative from each European country, the
International Society of Chemotherapy (ISC) and
the Federation of European Societies of Chemo-
therapy and Infection (FESCI). EUCAST also has a
Steering Committee, with a representative from
each of the six national breakpoint committees
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listed above, two representatives from the
EUCAST General Committee, and a Chairperson
and Scientific Secretary. All appointments to the
Steering Committee are made by the ESCMID
Executive Committee. This structure was estab-
lished in 2002 following a reorganisation of
EUCAST. EUCAST has Sub-committees on Anti-
fungal Susceptibility Testing (EUCAST AFST) and
on Expert Rules for Antimicrobial Susceptibility
Testing. The responsibility for development of
harmonised breakpoints rests with the Steering
Committee, in consultation with the national
breakpoint committees, the EUCAST General
Committee, the pharmaceutical industry and the
manufacturers of susceptibility testing devices.
During 2004 and 2005, EUCAST harmonised
breakpoints for several classes of antimicrobial
agents (aminoglycosides, fluoroquinolones, gly-
copeptides, oxazolidinones) [10], and during 2005
has set breakpoints for two new antimicrobial
agents, daptomycin and tigecycline, following the
procedure agreed with EMEA. It is currently
working on harmonisation of breakpoints for
carbapenems, cephalosporins, monobactams and
penicillins. The EUCAST AFST is currently work-
ing on European breakpoints for fluconazole.
EUCAST procedures for harmonising break-
points for existing antimicrobial agents, and for
setting breakpoints for new agents, are described
on the EUCAST website [11]. EUCAST breakpoint
tables can also be found on the EUCAST website
[10], with links to tables of wild-type MIC
distributions and rationale documents produced
for each of the antimicrobial agents addressed by
EUCAST.
Breakpoints defined by EUCAST are MIC break-
points. The International Standards Organization
(ISO) is currently developing a worldwide stand-
ard to determine MICs by microdilution. The
EUCAST [12] and the CLSI [13] microdilution
methods are both compatible with the final version
of the ISO method, which is currently being
distributed for an international vote on acceptance.
How laboratories will use and implement EUCAST
breakpoints will depend on the methods used in
individual laboratories. In order to facilitate the
process, EUCAST participated in a workshop
during November 2005 with pharmaceutical com-
panies and manufacturers of susceptibility testing
devices to discuss implementation of EUCAST
breakpoints in Europe. The various routes by
which implementation might be accomplished
were clarified:
• The manufacturers of automated susceptibility
testing systems can download EUCAST break-
points from the EUCAST website. It was agreed
that the time needed by the manufacturers to
implement breakpoints in their systems would
delay implementation in automated systems
Table 1. Format of data in EUCAST rationale documents and Technical Notes
Section title Section contents
1. Dosages Lists the known dosages used in European countries as ‘most common dose’, ‘maximum
dose’ and ‘administration forms available’.
2. MIC wild-type distributions Extensive MIC distribution data have been collected in an internet-based database freely
available to the public [15]. Excerpts from the database are listed in a table showing
numbers of isolates with MIC values in the wild-type distribution for each species.
3. Breakpoints before harmonisation For established agents, the existing breakpoints in each of the national systems are listed,
together with the current CLSI breakpoints [16] where available. This table will be
empty for new agents.
4. Pharmacokinetics A summary of the pharmacokinetic (Pk) data.
5. Pharmacodynamics A summary of the pharmacodynamic (Pd) data in vitro, in animal systems and clinical
data obtained from trials in humans.
6. Monte Carlo simulations and Pk ⁄Pd breakpoints Using simulated population pharmacokinetics, known Pd properties and probabilities of
target attainment, the theoretical Pk ⁄Pd breakpoint or breakpoints are determined for
various groups of microorganisms causing infection.
7. Clinical data Available clinical data in relation to known MIC values and resistance mechanisms are
evaluated.
8. Clinical breakpoints Preliminary clinical breakpoints based on clinical data and Pk ⁄Pd breakpoints are
defined. Species considered targets for the agent are listed. The preliminary breakpoints
are checked against MIC distributions for target species to ensure that wild-type
distributions are not divided by the breakpoints. To avoid cutting the wild-type
distribution, breakpoints may be adjusted one two-fold dilution step up or down.
9. Consultation process and breakpoint table Following the EUCAST consultation process, through which the national breakpoint
committees, the EUCAST General Committee members, the pharmaceutical industry and
the susceptibility testing devices industry are given the opportunity to comment on the
preliminary breakpoints, the final breakpoints are presented in a table.
10. Exceptions noted for individual national committees It is possible for a national committee to require an exception from the EUCAST
harmonised breakpoints (e.g., on the basis of different national dosages of the agent). The
exception will be noted in the rationale document and the reason given.
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until late 2006. The importance of informing the
manufacturers of new breakpoints as early as
possible was emphasised.
• EUCAST breakpoints will be implemented in
the susceptibility testing systems of the national
breakpoint committees in Europe. Disk-diffu-
sion susceptibility testing methods that imple-
ment EUCAST breakpoints include the BSAC
[14], CA-SFM [4] and SRGA [7] systems.
• Antimicrobial resistance surveillance systems
in which MIC values are collected can start
using EUCAST epidemiological cut-off values
and clinical breakpoints as they become avail-
able. The effects of changing breakpoints can be
assessed by retrospective comparison of data
interpreted by previous breakpoints and by
EUCAST breakpoints.
Beginning with the current issue, a series of
EUCAST Technical Notes (ETNs) will be pub-
lished in CMI. The ETN on daptomycin, recently
approved by EMEA, is the first to appear [17].
ETNs on aminoglycosides, fluoroquinolones,
glycopeptides and linezolid will follow in the
near future. The ETNs are based on the rationale
documents produced by EUCAST for each of the
antimicrobial agents subjected to the processes of
harmonising or setting breakpoints. The aim of
the ETNs is to highlight important background
information on which decisions concerning break-
points are made by EUCAST. The antimicrobial
agent-specific rationale documents will be avail-
able on the EUCAST website [10] and will be more
detailed than the ETNs. Both follow the format
and include the information outlined in Table 1.
The rationale documents will be updated when-
ever breakpoints are reviewed. The publication of
the ETNs in CMI will assist in the dissemination
of harmonised European breakpoints, provide
transparency to EUCAST decisions on break-
points, and provide references to EUCAST break-
points and the background to them.
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